AOTI, INC.
AOTI · AIM · Health Care · mcap £138m · 132.5p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 30 Sep 26 | Results | 2026 Interim Results
Significant progress towards obtaining Medicare coverage that will dramatically expand the growth potential for TWO2® therapy |
+0.0% |
| 27 Aug 26 | Proposed Topical Oxygen Therapy LCD Progress
This virtual open public meeting was intended to solicit stakeholder comments on the proposed language of the LCD ahead of its finalisation. |
−0.4% | |
| 27 Jul 26 | Trading update | Trading Statement
Half Year Trading Update and Notice of Results |
+11.4% |
| 24 Jul 26 | AOTI achieves transformational milestone
AOTI achieves transformational milestone that will dramatically expand the US addressable market and growth potential for its TWO2® therapy |
+32.6% | |
| 01 May 26 | Employee Share Purchase Plan
(AIM: AOTI), a medical technology group focused on delivering outcomes-based care at home, by more durable healing of wounds and the prevention of amputations, announces the establishment of an Employee Share Purchase Pl |
+12.5% | |
| 27 Apr 26 | Real-world study of AOTI’s TWO2® therapy
Large real-world study in 3,126 patients demonstrates superior durable healing of chronic wounds with AOTI's Topical Wound Oxygen (TWO2®) therapy |
+27.1% | |
| 21 Apr 26 | Results | 2025 Annual Report and Notice of AGM
2025 Annual Report and Notice of Annual General Meeting |
+0.0% |
| 30 Mar 26 | Results | Final Results
Good revenue growth despite US healthcare market disruption |
−13.6% |
| 23 Feb 26 | Full Year Trading Update and Notice of Results
Full Year Trading Update and Notice of Results |
−12.2% | |
| 06 Oct 25 | Appointment of Joint Corporate Broker
AOTI, INC., a medical technology group focused on the durable healing of wounds and prevention of amputations, is pleased to announce the appointment of Panmure Liberum Limited as Joint Corporate Broker, working alongsid |
+0.0% |
Company filings. Not investment advice.